Similarly, in mouse models of BRCA1-deficient ovarian cancer, PARP inhibition and immune checkpoint inhibition targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) increased T-cell tumor infiltration and interferon-gamma production, improving survival [42,43]. This evidence concerns the gene CTLA4 and ovarian cancer.